SGHT — Sight Sciences Share News
0.000.00%
Last trade - 00:00- $287.28m
- $242.86m
- $77.36m
Brief: Sight Sciences announces long-term safety and effectiveness data of standalone use of the Omni® surgical system in patients with open angle glaucoma
Sight Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sight Sciences Reports Second Quarter 2022 Financial Results
Sight Sciences Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Sight Sciences Reports First Quarter 2022 Financial Results
Brief: Sight Sciences Announces First Patient Treated In Trident European Trial To Evaluate The Omni® Surgical System In Pseudophakic Eyes With Open-Angle Glaucoma
Brief: Sight Sciences Reports Fourth Quarter And Full Year 2021 Financial Results
Brief: Sight Sciences Announces Preliminary Unaudited Fourth Quarter And Full Year 2021 Financial Results
Brief: Sight Sciences Receives FDA 510(K) Clearance Of The Tearcare System For Treatment Of Meibomian Gland Dysfunction (Mgd), The Leading Cause Of Dry Eye Disease
Sight Sciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Sight Sciences Posts Q3 Loss Per Share Of $0.43
Brief: Sight Sciences Files Lawsuit Against Ivantis For Patent Infringement
Brief: Sight Sciences - Publication Of Favorable Two-Year Outcomes Of Standalone Use Of Omni Surgical System In Mild To Moderate Open-Angle Glaucoma
Brief: Sight Sciences Reports Second Quarter 2021 Financial Results
Brief: Sight Sciences Inc Shares Open 25% Above IPO Price In Nasdaq Debut
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:28 AM